FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322771015> ?p ?o ?g. }

• W4322771015 endingPage "43" @default.
• W4322771015 startingPage "P6" @default.
• W4322771015 abstract "Abstract Background: The EuroQol- 5 Dimension (EQ-5D) is a generic patient-reported outcome measure widely used to capture meaningful change in health-related quality of life between treatments to inform drug and health technology reimbursement decision making. We investigated the construct validity of EQ-5D-5L in women with breast cancer. Methods: This study included adult women diagnosed with stage I to IV breast cancer, who completed the EQ-5D-5L and the Edmonton Symptom Assessment System (ESAS) during outpatient clinic visits at two academic cancer centres in Toronto. We evaluated construct validity through assessing known-group validity and convergent/divergent validity. For known-group validity, the primary analysis tested the hypothesis that EQ-5D-5L could adequately discriminate between patients with metastatic disease and early-stage disease; secondary analyses addressed utility values between women in breast-cancer associated health states. A suggested minimally important difference (MID) for the Canadian scoring of the EQ-5D-5L is 0.037; we evaluated whether the lower bound of the 95% confidence interval (95%CI) exceeded this value. In terms of convergent/divergent validity, the primary analysis tested the hypothesis that EQ-5D-5L mean utility values for each health state (HS) would be at least moderately correlated with ESAS total symptom distress score (SDS) (|r|&gt;0.30) using Wilcoxon rank-sum tests and Spearman’s correlation tests. Construct validity was considered as acceptable if the hypotheses of the primary analysis are satisfied. Results: We recruited 549 women, 406 (74%) with early-stage disease and 143 (26%) with metastatic disease (HS5), with a mean age of 57 (SD 12); 412 (75%) had been diagnosed with breast cancer in the 7 years prior to recruitment and were receiving active treatment for their cancer. The mean utility value for early-stage breast cancer was 0.84 (95% CI 0.83-0.86) and for metastatic breast cancer (0.78, 95% CI 0.76-0.81). This difference was 0.060 (95% CI 0.036 to 0.085, p&lt; 0.001) with the lower bound of the confidence interval slightly less than the prespecified MID (0.037). There was no significant difference between the mean utility value for women in the first year after primary breast cancer diagnosis (HS1), and women in their second to fifth year after a primary breast cancer treated with curative intent (HS3) or between women in HS1 and women in their sixth and following years after a primary breast cancer treated with curative intent (HS4). EQ-5D-5L also did not discriminate between women in HS3 and HS4. For convergent/divergent validity, there was a negative correlation between utility values and ESAS physical, emotional and total SDSs. EQ-5D-5L and ESAS total SDSs correlation coefficients were higher than 0.30 for all health states. Conclusion: EQ-5D-5L met criteria for convergent/divergent validity in women with breast cancer. The tests for discriminant validity were equivocal, suggesting more research is needed for assessing construct validity with a larger sample size. Table 1. EQ-5D-5L Utility Values. N= number; Std Dev= standard deviation; IQR= interquartile range; CI= confidence interval Citation Format: Sofia Torres, Maureen Trudeau, Geoffrey Liu, Nicholas Mitsakakis, Ahmed Bayoumi. Validity of EQ-5D-5L for women with breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-05-43." @default.
• W4322771015 created "2023-03-03" @default.
• W4322771015 creator A5013209367 @default.
• W4322771015 creator A5023531951 @default.
• W4322771015 creator A5027209386 @default.
• W4322771015 creator A5047113165 @default.
• W4322771015 creator A5083651358 @default.
• W4322771015 date "2023-03-01" @default.
• W4322771015 modified "2023-09-26" @default.
• W4322771015 title "Abstract P6-05-43: Validity of EQ-5D-5L for women with breast cancer" @default.
• W4322771015 doi "https://doi.org/10.1158/1538-7445.sabcs22-p6-05-43" @default.
• W4322771015 hasPublicationYear "2023" @default.
• W4322771015 type Work @default.
• W4322771015 citedByCount "0" @default.
• W4322771015 crossrefType "journal-article" @default.
• W4322771015 hasAuthorship W4322771015A5013209367 @default.
• W4322771015 hasAuthorship W4322771015A5023531951 @default.
• W4322771015 hasAuthorship W4322771015A5027209386 @default.
• W4322771015 hasAuthorship W4322771015A5047113165 @default.
• W4322771015 hasAuthorship W4322771015A5083651358 @default.
• W4322771015 hasConcept C105795698 @default.
• W4322771015 hasConcept C121244757 @default.
• W4322771015 hasConcept C121608353 @default.
• W4322771015 hasConcept C126322002 @default.
• W4322771015 hasConcept C12868164 @default.
• W4322771015 hasConcept C139265228 @default.
• W4322771015 hasConcept C159110408 @default.
• W4322771015 hasConcept C159744936 @default.
• W4322771015 hasConcept C171606756 @default.
• W4322771015 hasConcept C182050348 @default.
• W4322771015 hasConcept C1862650 @default.
• W4322771015 hasConcept C206041023 @default.
• W4322771015 hasConcept C2778464720 @default.
• W4322771015 hasConcept C2779134260 @default.
• W4322771015 hasConcept C2779951463 @default.
• W4322771015 hasConcept C29456083 @default.
• W4322771015 hasConcept C3018868096 @default.
• W4322771015 hasConcept C3019006561 @default.
• W4322771015 hasConcept C33923547 @default.
• W4322771015 hasConcept C44249647 @default.
• W4322771015 hasConcept C49453240 @default.
• W4322771015 hasConcept C530470458 @default.
• W4322771015 hasConcept C70410870 @default.
• W4322771015 hasConcept C71924100 @default.
• W4322771015 hasConceptScore W4322771015C105795698 @default.
• W4322771015 hasConceptScore W4322771015C121244757 @default.
• W4322771015 hasConceptScore W4322771015C121608353 @default.
• W4322771015 hasConceptScore W4322771015C126322002 @default.
• W4322771015 hasConceptScore W4322771015C12868164 @default.
• W4322771015 hasConceptScore W4322771015C139265228 @default.
• W4322771015 hasConceptScore W4322771015C159110408 @default.
• W4322771015 hasConceptScore W4322771015C159744936 @default.
• W4322771015 hasConceptScore W4322771015C171606756 @default.
• W4322771015 hasConceptScore W4322771015C182050348 @default.
• W4322771015 hasConceptScore W4322771015C1862650 @default.
• W4322771015 hasConceptScore W4322771015C206041023 @default.
• W4322771015 hasConceptScore W4322771015C2778464720 @default.
• W4322771015 hasConceptScore W4322771015C2779134260 @default.
• W4322771015 hasConceptScore W4322771015C2779951463 @default.
• W4322771015 hasConceptScore W4322771015C29456083 @default.
• W4322771015 hasConceptScore W4322771015C3018868096 @default.
• W4322771015 hasConceptScore W4322771015C3019006561 @default.
• W4322771015 hasConceptScore W4322771015C33923547 @default.
• W4322771015 hasConceptScore W4322771015C44249647 @default.
• W4322771015 hasConceptScore W4322771015C49453240 @default.
• W4322771015 hasConceptScore W4322771015C530470458 @default.
• W4322771015 hasConceptScore W4322771015C70410870 @default.
• W4322771015 hasConceptScore W4322771015C71924100 @default.
• W4322771015 hasIssue "5_Supplement" @default.
• W4322771015 hasLocation W43227710151 @default.
• W4322771015 hasOpenAccess W4322771015 @default.
• W4322771015 hasPrimaryLocation W43227710151 @default.
• W4322771015 hasRelatedWork W2003595257 @default.
• W4322771015 hasRelatedWork W2033513121 @default.
• W4322771015 hasRelatedWork W2089003843 @default.
• W4322771015 hasRelatedWork W2137445126 @default.
• W4322771015 hasRelatedWork W2906299562 @default.
• W4322771015 hasRelatedWork W2984948722 @default.
• W4322771015 hasRelatedWork W3209003011 @default.
• W4322771015 hasRelatedWork W4220925820 @default.
• W4322771015 hasRelatedWork W4282927283 @default.
• W4322771015 hasRelatedWork W4322771015 @default.
• W4322771015 hasVolume "83" @default.
• W4322771015 isParatext "false" @default.
• W4322771015 isRetracted "false" @default.
• W4322771015 workType "article" @default.